The company remains pre-revenue with operating losses widening to $122.1 million in 2025Q3, driven by a steady increase in quarterly R&D expenditures from $29.9 million in 2024Q3.
| Sales/Revenue | 0 | 0 | 0 |
| Revenue Growth % | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin % | - | - | - |
| Gross Profit Growth % | - | - | - |
| Operating Expenses | 337.51M | 224.83M | 43.67M |
| OpEx % of Revenue | - | - | - |
| Selling, General & Admin | 44.86M | 26.8M | 15.04M |
| SG&A % of Revenue | - | - | - |
| Research & Development | 220.3M | 107.52M | 15.56M |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 2.13M | 90.52M | 13.06M |
| Operating Income | -337.51M | -224.83M | -43.67M |
| Operating Margin % | - | - | - |
| Operating Income Growth % | - | -414.86% | - |
| EBITDA | -337.48M | -224.82M | -43.67M |
| EBITDA Margin % | - | - | - |
| EBITDA Growth % | - | -414.85% | - |
| D&A (Non-Cash Add-back) | 35K | 14K | 2K |
| EBIT | -393.97M | -218.24M | -47.21M |
| Net Interest Income | 17.83M | 5.96M | 1.92M |
| Interest Income | 17.98M | 6.18M | 1.92M |
| Interest Expense | 152K | 223K | 0 |
| Other Income/Expense | 14.71M | 6.37M | -3.54M |
| Pretax Income | -322.81M | -218.47M | -47.21M |
| Pretax Margin % | - | - | - |
| Income Tax | -8.4M | -9.34M | 0 |
| Effective Tax Rate % | 2.6% | 4.27% | 0% |
| Net Income | -314.41M | -209.13M | -47.21M |
| Net Margin % | - | - | - |
| Net Income Growth % | - | -343.01% | - |
| Net Income (Continuing) | -314.41M | -209.13M | -47.21M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | -2.99 | -2.03 | -0.95 |
| EPS Growth % | - | -113.68% | - |
| EPS (Basic) | - | -2.03 | -0.95 |
| Diluted Shares Outstanding | 105.03M | 103.04M | 49.94M |
| Basic Shares Outstanding | 105.03M | 103.04M | 49.94M |
| Dividend Payout Ratio | - | - | - |
Clinical trial execution failure
As reported in recent financial statements, Metsera's quarterly research and development expenditures have climbed steadily from $29.9 million in 2024Q3 to $63.7 million by 2025Q3, reflecting an aggressive acceleration in clinical trial activity and the advancement of the company's lead metabolic therapeutic candidates.
The consistent quarter-over-quarter increase in R&D spending suggests a management team prioritizing rapid clinical validation over near-term expense containment. Investors should monitor whether this trajectory remains sustainable given the company's current cash position and the high-stakes nature of the competitive metabolic disease landscape.
Based on the company's reported figures, operating losses have widened significantly, reaching $122.1 million in 2025Q3, which underscores the lack of operational scale inherent in a pre-revenue biotechnology firm currently funding intensive, multi-asset clinical development programs across its proprietary NuSH platform.
The divergence between rising SG&A and R&D costs relative to zero revenue indicates that the company is currently in a pure capital-consumption phase. This structure implies that operating efficiency will remain elusive until the company achieves a major clinical milestone or enters into a strategic partnership.
According to recent SEC filings, Metsera's net loss reached $116.2 million in 2025Q3, a figure that primarily reflects the heavy investment in intellectual property and clinical trial infrastructure rather than operational inefficiency or structural cost overruns within the core business model.
The quality of these earnings is typical for a clinical-stage entity, where net income is a secondary metric to the progress of the pipeline. Analysts should focus on the burn rate relative to the $352.4 million cash position to assess the timing of potential future equity dilution.
Data from the latest quarterly reports suggest that Metsera's cash burn is accelerating, with the company recording a $122.1 million operating loss in 2025Q3, which may force management to seek additional capital markets access sooner than the current market consensus might anticipate.
While the current cash position provides a temporary buffer, the rapid escalation in R&D spending warrants caution regarding the company's long-term funding requirements. Investors should consider the risk that clinical delays could exacerbate this burn rate, leading to significant shareholder dilution in the coming fiscal periods.
Quick answers to the most common questions about buying MTSR stock.
For fiscal year 2024, Metsera, Inc. (MTSR) reported total revenue of $0.0M.
Metsera, Inc. (MTSR) reported a net loss of $209.1M for the fiscal year ending 2024.